Stem Cell

Stem Cell

ICO Ended
13,218 Views
At SCI, we are devoted to the international research, development, and implementation of stem cell therapy. We are also expanding our network with professionals, labs, clinics, hospitals, and nonprofit organizations. Our ultimate goal at SCI is to connect people who need treatment with the right dedicated solutions and professionals for their unique needs. At SCI, we believe such connections should be convenient and at your fingertips, just as so many other services are in modern society. We imagine a world where each and every person, no matter where they come from, will be able to connect with a Stem Cel Specialist instantly through our Stem Cell Innovations application (SCI Application), and in the same connection be able to decide when and how much confidential information to share with professionals.
8.4
TOTAL SCORE
8.1
ICO PROFILE

(weight: 45%)

10
TEAM PROOF

(weight: 20%)

Get widget
General
Website: Visit
White paper: Read
Pre-sale Time: 17 Sept 2018 - 09 Oct 2018
ICO Time: 21 Nov 2018 - 17 Jan 2019
Whitelist/KYC: KYC
Country: Gibraltar
Token info
Ticker: SCI
Platform: Ethereum
Token Type: ERC20
Available for sale: 800,000,000 SCI
Financial
ICO Price: 1 SCI = 0.15 USD
Accepting: BTC, ETH, LTC, Fiat
Soft cap: 3,000,000 USD
Hard cap: 36,000,000 USD
2013
Establishment of Camden RAD, LLC, a company devoted to stem cell research and development.
Q4 2017
Camden RAD, LLC is rebranded as Stem Cell Innovations, and a new company is established, based on blockchain technology.<br /> <br /> Advanced research begins to determine market and development opportunities.
Q1 2018
Attended Token 2049 conference in Hong Kong.<br /> <br /> Attended Stem Cell Summit at the University of California in Los Angeles (UCLA).<br /> <br /> Attended CBC conference in San Francisco, CA.<br />
Q2 2018
Attended ICO20 Summit in Santa Monica, CA.<br /> <br /> Integration of smart contract technology is established.<br /> <br /> Company headquarters incorporated in Gibraltar, GB.<br /> <br /> Strategic efforts toward development begins.<br /> <br /> Interviews with potential medical participants take place.
Q3 2018
Whitelist is scheduled to go live.<br /> <br /> Token Sale starts.
Q4 2018
Token Sale ends and min max caps are assessed.<br /> <br /> Distribution of Tokens to participants through ERC20 will commence.
Q1 2019
SCI will begin final testing and reporting based on blockchain technology being used.<br /> <br /> Creation of a non-identical patient identification factor on Passive Blockchain Node will be initialized.<br /> <br /> Demo testing for SCI Application v 1.0 will begin.
Q2 2019
Release of the SCI Application v1.1<br /> <br /> Enrollment begins for doctors, patients, and stem cell laboratories in the United States
Q3 2019
Release of Market Surveillance strategy for further growth<br /> <br /> Release SCI Application v2.0<br /> <br /> Enrollment begins for professionals, patients, and stem cell laboratories in Middle East and across North Africa.<br /> <br /> Announcement of first SCI Lab location and franchise expansion plan.
Q4 2019
Announcement of clinical development and research strategy in the stem cell field.<br /> <br /> Public announcement regarding SCI achievements to date.<br /> <br /> First ever online synthetic stem cell purchase through the SCI Application. Release SCI Application v3.0, fully functional platform for professionals and patients.
Q1 2020
Stem Cell Lab Evaluation report per first year of operation and development.<br /> <br /> Release SCI earnings and financials report.<br /> <br /> Release results of SCI's stem cell research and development to date.<br />
Q2 2020
Expansion of SCI stem cell labs and clinics in China, Japan, South Korea, and India.<br /> <br /> Begin charging membership fees (payable in Stem Cell Innovations tokens) for professional-facing portion of SCI application.
Q3 2020
Begin second phase of SCI stem cell research and development.<br /> <br /> Release SCI Application v3.5, including professional-facing component to help practitioners become more involved in the stem cell research space and contribute to the network.
Q4 2020
Expansion and acquisition of SCI stem cell labs and clinics in Europe.
Q1 2021
Release SCI earnings and financials report for second year operation and development.<br /> <br /> Release public update on SCI stem cell research and development.<br /> <br /> Stem Cell Lab Evaluation report for second year.
Q2 2021
Release SCI Application v4.0 including:<br /> <br /> A new platform for medical students, universities, and hospitals to engage with the SCI Application.<br /> <br /> Fully Functional EMR Worldwide Enforcing HIPPA and expanding of synthetic stem cell delivery to Latin America.
Screenshots taken on 13 Sep 2018
Moe Galal
Chief Executive Officer / Founder
Participates in a number of projects
Ben Barel
Chief Operations Officer / Co-Founder
Participates in a number of projects
Ali Alrashidi
Chief Technology Officer / Co-Founder
Participates in a number of projects
Matt Galal
Chief of Staff / Co-Founder
Participates in a number of projects
Kobi Barel
Operations Engineer / Co-Founder
Participates in a number of projects
John Glavinovich, M.D.
Medical Director
Participates in a number of projects
Philip Glukhovsky, D.C.
Health Informatics Manager
Participates in a number of projects
Roger Williams
VP of Marketing
Participates in a number of projects
Liz Curlett
VP, PR & Corporate Communications
Participates in a number of projects
Candice Kouchache
Business Development
Participates in a number of projects
Ahmed Elsantawi
VP of International Human Resources
Participates in a number of projects
David Marmon
Web Designer
Participates in a number of projects
Heather Deveaux
Copywriter
Participates in a number of projects
Everlecia Taylor
Creative Writer
Participates in a number of projects
Marina Evglevskaya
Administrative Manager
Participates in a number of projects
Rakel Apodaca
Product Manager
Participates in a number of projects
Michelle Chavon
Marketing
Participates in a number of projects

Advisors (7)

Boyan Josic
Participates in a number of projects
Marc X. Ellul
Participates in a number of projects
Roger Shortz, M.D.
Participates in a number of projects
Greg Maddex, D.O
Participates in a number of projects
Pantea Nakieen, M.D.
Participates in a number of projects
Shahab Sajadi
Participates in a number of projects
Igor Soshkin
Participates in a number of projects
HEIGHT - 0px
WIDTH - 0px
PUT THIS CODE TO YOUR WEBSITE
ICO List
Other Interesting ICOs
Active
tokenforge
Tokenforge is a Germany-based infrastructure provider for the compliant tokenization of Real-World Assets (RWA). Since 2021, it has launched over 30 TokenSuite instances across five EU jurisdictions, fully aligned with MiCAR, eWpG, MiFID II, and national frameworks. The core product, TokenSuite, is API-first and modular, integrating KYC/KYB, e-signatures, custody, payments, and other regulated third-party services. Built under BaFin oversight, tokenforge integrates blockchain technology with traditional financial infrastructure. TokenSuite includes regulated services such as KYC, custody, payments, and registrar functions, ensuring compliance across different jurisdictions. The infrastructure will be expanded with EchoLayer, a decentralized network layer that enables cross-platform asset interaction, affiliate programs, and shared market access. Complementing this, IRIS is an AI-powered insights engine in development, designed to provide advanced analytics and decision support for asset structuring, placement, and lifecycle management within the ecosystem. At the core of tokenforge’s infrastructure is $TKFG, the native utility token. It enables issuers to access a 20% discount on service fees through staking and unlocks further benefits as the ecosystem evolves. tokenforge’s infrastructure is designed for institutional-grade scalability and positions itself as a foundational layer for the regulated digital asset industry in Europe.
Active
LERN360
LERN360 is a blockchain-powered, AI-enhanced decentralized learning platform that offers multilingual, skill-based education and incentivizes learners and educators with tokenized rewards. The platform transforms global education through verifiable and accredited micro-credentials, smart learning, and learn-to-earn models.
Active
Rivalz
Rivalz is redefining AI infrastructure by creating an AI Intel Layer to unlock new agentic economies. Built on a dual-chain DePIN architecture using Dymension and Arbitrum, Rivalz addresses one of the biggest bottlenecks in AI today: access to AI-ready, verifiable, and secure data. As we envision the web3 space to become agentic and overtake humans in the amount of transactions over time, what Rivalz is building is key for enabling this future. The core challenge that Rivalz is addressing is the need for AI-ready, verifiable and accessible data and later on intelligence. Rivalz offers a hybrid solution combining decentralized storage and high-speed agent-centric connectivity networks that cater specifically to AI's demands, ushering in the era of the agentic economy.
Upcoming
MediLOT
MediLOT is a health data protocol that aims to solve the concerns of Electronic Health Records (EHR). Current EHR systems are fragmented, centralised and lack patient ownership. Through a dual blockchain solution, MediLOT incorporates Artificial Intelligence capabilities onboard its control and data layers which allows the equitable sharing of health data. The MediLOT ecosystem will consist of patients, healthcare providers, researchers and commercial companies.
Upcoming
Earth Token
The Natural Asset Exchange blockchain platform and Earth Token cryptocurrency initial coin offering (ICO) token sale provides a unique opportunity to truly transform the Natural Capital Asset market, by creating a Natural Asset Marketplace that allows all stakeholders in the climate value chain to participate.
Upcoming
Aimedis
Aimedis is an AI backed, blockchain and smart contract supported medical ecosystem, that changes the way patients, doctors, and hospitals communicate, connect and handle information. Using the Aimedis platform, users can store, secure and share their medical information only with the people they want to share it with by using the Aimedis right management system. Beside the records, AImedis offers videochat and communication with other patients and doctors, online prescriptions, online appointments, learning content, the inclusion of fitness trackers and devices like ECG or bloodpressure monitors into the system, while all transactions inside the system are backed by our porprietary private AIMChain blockchain, while the token is bound to a public blockchain (Aimedis dual-blockchain model). AIMSocial will be the new incentivised and decentralized medical social network where patients can help other patients and get rewarded for it, while the system is supported by AI.